ACADIA Pharmaceuticals ACAD
$17.11 −$0.48 (-2.73%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $17.12 +0.06%
Open$17.47
Prev close$17.59
Day range$17.05 – $17.79
Volume1.90M
Market cap$2.96B
P/E (TTM)8.1
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$342.29M+22.8% YoY
Operating profit$71.72M+100.6% YoY
Net profit$53.52M-25.4% YoY
Diluted EPS$0.31-26.2% YoY
Free cash flow$10.26M+141.2% YoY
Operating cash flow$11.50M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin90.5%
Operating margin10.2%
Net margin30.1%
Return on equity31.4%
Return on assets23.2%
Return on invested capital28.2%
Current ratio3.82
Liabilities / assets22.7%
Cash & investments$976.45M
Total debt$57.32M
Net cash (debt)$919.12M
Free cash flow / sales15.0%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $342.29M | $307.96M | $268.06M | $1.07B | $283.99M |
| Total Operating Revenue | $342.29M | $307.96M | $268.06M | $1.07B | $283.99M |
| Cost of Revenue | $35.09M | $28.32M | $24.79M | $89.00M | $26.23M |
| Gross Profit | $307.20M | $279.64M | $243.27M | $982.51M | $257.76M |
| Operating Expense | $235.48M | $241.81M | $247.89M | $877.70M | $240.37M |
| Selling and Admin Expenses | $159.20M | $160.25M | $171.02M | $548.89M | $155.62M |
| Research & Development | $76.28M | $81.56M | $76.87M | $328.80M | $84.76M |
| Operating Profit | $71.72M | $37.84M | -$4.62M | $104.81M | $17.39M |
| Net Non-Operating Interest Income (Expense) | $8.42M | $7.99M | $8.06M | $31.72M | $8.33M |
| Non-Operating Interest Income | $8.42M | $7.99M | $8.06M | $31.72M | $8.33M |
| Other Income (Expense) | $300,000.00 | $647,000.00 | $542,000.00 | $2.37M | $596,000.00 |
| Other Non-Operating Income (Expenses) | $300,000.00 | $647,000.00 | $542,000.00 | $2.37M | $596,000.00 |
| Pretax Profit | $80.44M | $46.47M | $3.98M | $138.90M | $26.32M |
| Tax | $26.92M | $14.97M | $344,000.00 | -$252.10M | -$247.25M |
| Net Profit | $53.52M | $31.50M | $3.64M | $391.00M | $273.57M |
| Profit from Continuing Operations | $53.52M | $31.50M | $3.64M | $391.00M | $273.57M |
| Net Income to Parent Company | $53.52M | $31.50M | $3.64M | $391.00M | $273.57M |
| Net Income to Common Stockholders | $53.52M | $31.50M | $3.64M | $391.00M | $273.57M |
| Basic EPS | $0.31 | $0.18 | $0.02 | $2.32 | $1.62 |
| Diluted EPS | $0.31 | $0.18 | $0.02 | $2.30 | $1.60 |
| Special Income (Charges) | – | – | – | $0.00 | – |
| -Gain on Sale of Property/Plant/Equipment | – | – | – | $0.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.79B | $1.74B | $1.61B | $1.56B | $1.56B |
| Total Current Assets | $1.27B | $1.22B | $1.10B | $1.06B | $1.06B |
| Cash and Cash Equivalents & Short-Term Investments | $976.45M | $956.47M | $851.46M | $819.69M | $819.69M |
| -Cash and Cash Equivalents | $322.37M | $384.99M | $282.21M | $177.70M | $177.70M |
| -Short Term Investments | $654.08M | $571.49M | $569.25M | $641.99M | $641.99M |
| Receivables | $178.32M | $166.33M | $148.38M | $148.23M | $148.23M |
| -Accounts Receivable | $161.02M | $150.64M | $135.35M | $121.46M | $121.46M |
| -Accrued Interest Receivable | $17.30M | $15.69M | $13.03M | $26.77M | $26.77M |
| Prepaid Assets | $73.31M | $69.37M | $64.60M | $59.53M | $59.53M |
| Inventory | $40.36M | $32.37M | $31.57M | $34.67M | $34.67M |
| Total Non-Current Assets | $525.73M | $518.36M | $509.21M | $502.08M | $502.08M |
| Net PPE | $85.87M | $86.53M | $60.93M | $54.87M | $54.87M |
| -Gross PPE | $85.87M | $86.53M | $60.93M | $64.35M | $64.35M |
| Goodwill and Other Intangible Assets | $135.48M | $103.45M | $106.17M | $108.89M | $108.89M |
| Non-Current Deferred Assets | $226.72M | $240.68M | $249.62M | $249.88M | $249.88M |
| Other Non-Current Assets | $77.65M | $87.70M | $92.49M | $88.45M | $88.45M |
| Total Liabilities | $406.66M | $436.29M | $357.16M | $336.81M | $336.81M |
| Total Current Liabilities | $332.22M | $361.44M | $305.52M | $277.11M | $277.11M |
| Payables | $16.33M | $44.57M | $12.25M | $11.21M | $11.21M |
| -Accounts Payable | $16.33M | $44.57M | $12.25M | $10.90M | $10.90M |
| Current Accrued Expenses | $256.97M | $267.22M | $250.06M | $208.70M | $208.70M |
| Short-Term Debt and Capital Lease Obligation | $14.53M | $14.31M | $11.79M | $11.63M | $11.63M |
| -Current Capital Lease Obligation | $14.53M | $14.31M | $11.79M | $11.63M | $11.63M |
| Total Non-Current Liabilities | $74.45M | $74.86M | $51.64M | $59.69M | $59.69M |
| Long Term Debt and Capital Lease Obligation | $57.32M | $59.55M | $39.00M | $40.55M | $40.55M |
| -Long Term Capital Lease Obligation | $57.32M | $59.55M | $39.00M | $40.55M | $40.55M |
| Other Non-Current Liabilities | $17.12M | $15.31M | $12.64M | $19.14M | $19.14M |
| Total Equity | $1.39B | $1.31B | $1.25B | $1.23B | $1.23B |
| Stockholders' Equity | $1.39B | $1.31B | $1.25B | $1.23B | $1.23B |
| Capital Stock | $17,000.00 | $16,000.00 | $16,000.00 | $16,000.00 | $16,000.00 |
| -Common Stock | $17,000.00 | $16,000.00 | $16,000.00 | $16,000.00 | $16,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $3.12B | $3.09B | $3.06B | $3.04B | $3.04B |
| Retained Earnings | -$1.72B | -$1.78B | -$1.81B | -$1.81B | -$1.81B |
| Gains/Losses Not Affecting Retained Earnings | -$2.94M | -$958,000.00 | -$563,000.00 | $1.45M | $1.45M |
| -Accumulated Depreciation | – | – | – | -$9.48M | -$9.48M |
| -Total Tax Payable | – | – | – | $304,000.00 | $304,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $11.50M | $100.78M | $33.98M | $109.84M | -$48.73M |
| Net cash flow from continuing operations | $11.50M | $100.78M | $33.98M | $109.84M | -$48.73M |
| Net Income from Continuing Operations | $53.52M | $31.50M | $3.64M | $391.00M | $273.57M |
| Depreciation & Depletion & Amortization | $3.65M | $3.16M | $2.99M | $11.76M | $2.92M |
| Deferred Tax | $14.40M | $9.77M | -$94,000.00 | – | – |
| Change in Working Capital | -$77.55M | $39.46M | $13.20M | -$89.76M | -$87.91M |
| -Change in Receivables | -$12.02M | -$17.96M | -$153,000.00 | -$43.54M | -$8.80M |
| -Change in Inventory | $1.36M | $3.90M | $78,000.00 | -$18.20M | -$4.89M |
| -Change in Prepaid Assets | -$3.90M | -$4.77M | -$5.07M | -$3.85M | $1.34M |
| -Change in Payables and Accrued Expense | -$64.75M | $54.85M | $24.90M | -$24.55M | -$79.24M |
| -Change in Other Current Assets | $2.84M | $2.61M | $2.13M | $5.81M | $1.35M |
| -Change in Other Current Liabilities | -$1.09M | $822,000.00 | -$8.68M | -$5.44M | $2.33M |
| Net cash flow from investing | -$86.15M | -$8.53M | $66.28M | -$302.56M | -$55.87M |
| Net Cash Flow from Continuing Investing Activities | -$86.15M | -$8.53M | $66.28M | -$302.56M | -$55.87M |
| Net PPE Purchase and Sale | -$1.24M | -$5.09M | -$5.21M | -$4.69M | -$4.01M |
| Net Investment Purchase and Sale | -$84.91M | -$3.44M | $71.49M | -$199.04M | -$51.86M |
| Financing Cash Flow | $11.87M | $10.49M | $4.23M | $49.88M | $22.67M |
| Net Cash Flow from Continuing Financing Activities | $11.87M | $10.49M | $4.23M | $49.88M | $22.67M |
| Net Common Stock Issuance | $11.87M | $10.49M | $4.23M | $49.88M | $22.67M |
| Ending Cash Balance | $330.21M | $392.83M | $290.06M | $185.54M | $185.54M |
| Net Change in Cash | -$62.78M | $102.75M | $104.49M | -$142.85M | -$81.93M |
| Beginning Cash Balance | $392.83M | $290.06M | $185.54M | $328.36M | $267.47M |
| Effect of Exchange Rate Changes | $159,000.00 | $27,000.00 | $25,000.00 | $26,000.00 | $7,000.00 |
| Free Cash Flow | $10.26M | $95.69M | $28.77M | $105.15M | $46.10M |
| Net Intangibles Purchase and Sale | – | – | $0.00 | – | – |
| Other Non-Cash Items | – | – | – | -$249.88M | – |
| Net Business Purchase and Sale | – | – | – | -$98.84M | – |
No comments yet — be the first to weigh in on ACAD.
Sign in to join the discussion.